Investors
Invest in innovation that has the potential to transform healthcare
Company Overview
Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device.
Stock Information
Change
Volume
Market Cap